Only a few days to go: We’re raising £25,000 to keep TheyWorkForYou running and make sure people across the UK can hold their elected representatives to account.

Donate to our crowdfunder

Palbociclib

Department of Health written question – answered on 15th February 2017.

Alert me about debates like this

Photo of Tom Brake Tom Brake Liberal Democrat Spokesperson (Foreign Affairs), Liberal Democrat Chief Whip, Liberal Democrat Shadow Leader of the House of Commons

To ask the Secretary of State for Health, if he will take steps to ensure that palbociclib is made available to all eligible breast cancer patients.

Photo of Nicola Blackwood Nicola Blackwood The Parliamentary Under-Secretary of State for Health

Through its technology appraisal programme, the National Institute for Health and Care Excellence (NICE) provides independent, evidence-based guidance for the National Health Service on whether drugs and treatments represent a clinically and cost effective use of NHS resources. NICE is currently appraising Palbociclib in combination with an aromatase inhibitor for treating hormone receptor-positive, human epidermal growth factor receptor 2-negative, locally advanced or metastatic breast cancer in adults. NICE published its draft guidance on 3 February and stakeholders have until 24 February to comment on its draft recommendations. NICE expects to publish its final guidance in June 2017.

Does this answer the above question?

Yes0 people think so

No0 people think not

Would you like to ask a question like this yourself? Use our Freedom of Information site.